TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29361097
Drug: Fluctuating between
Normalized name: CYCLIZED P12 (PEPTIDE BOND BETWEEN THE CARBOXY AND AMINO-TERMINAL ENDS OF THE LINEAR PEPTIDE PSHISKYILRWRPK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluctuating between complete and partial remission during maintenance treatment
Study: 29361435
Drug: SGM-101 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: SGM-101 (10 mg) administered intravenously 4 days before surgery
Study: 29361470
Drug: Prexasertib 105
Normalized name: Prexasertib
DrugBank: Prexasertib (DB12008)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prexasertib 105 mg/m administered intravenously
Study: 29362251
Drug: Evaluation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluation of key performance measures such as time to first ECG, receipt of troponin testing, receipt of reperfusion therapy for ST segment elevation ACS, provision of angiography for troponin-positive patients.
Study: 29362665
Drug: Paricalcitol (Vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paricalcitol (Vitamin D receptor activation)
Study: 29362685
Drug: Artesunate-amodiaquine fixed-dose
Normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Artesunate-amodiaquine fixed-dose combination tablets (ASAQ Winthrop®)
Study: 29362724
Drug: Suboptimal antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suboptimal antiretroviral therapy adherence (<100%)
Study: 29362724
Drug: Optimal antiretroviral
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal antiretroviral therapy adherence (≥100%)
Study: 29363235
Drug: E7777 (6,
Approvals — FDA: no, EMA: no, PMDA: no
Description: E7777 (6, 12, and 9 μg/kg/day)
Study: 29363235
Drug: E7777 (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: E7777 (9 μg/kg/day)
Study: 29363446
Drug: Tetravalent dengue
Normalized name: dengue virus live antigen, CYD serotype 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetravalent dengue DNA vaccine (TVDV) formulated in Vaxfectin
Study: 29363651
Drug: Remote Ischemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote Ischemic Conditioning (RIC) consisting of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuffs on bilateral upper limbs twice a day for 90 days.
Study: 29364886
Drug: VRC01LS intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRC01LS intravenous (IV) infusion at 20 mg/kg
Study: 29364886
Drug: VRC01LS intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRC01LS intravenous (IV) infusion at 40 mg/kg
Study: 29364886
Drug: VRC01LS intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRC01LS intravenous (IV) administration at 5 mg/kg
Study: 29364886
Drug: VRC01LS subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRC01LS subcutaneous (SC) administration at 5 mg/kg
Study: 29364886
Drug: VRC01LS IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRC01LS IV dose range of 5-40 mg/kg
Study: 29365099
Drug: Teriparatide 20
Normalized name: TERIPARATIDE 200UNT/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide 20 µg administered by subcutaneous injection daily for 104 weeks
Study: 29366510
Drug: Targeted treatment
Normalized name: benzoyl peroxide 25 mg in 1 mL TOPICAL SWAB [SkinPharmacy Advanced Acne Therapy Targeted Treatment Wipes]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted treatment based on molecular alterations identified from tumor biopsy
Study: 29366960
Drug: Gemcitabine (1000-1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1000-1250 mg/kg over 30-60 min i.v infusion)
Study: 29368271
Drug: Anti-CCP2 antibody
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-CCP2 antibody positive patients (Gp1-3)
Study: 29368271
Drug: Anti-CCP2 antibody
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-CCP2 antibody negative patients
Study: 29368632
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of suPAR and syndecan-4 with Pneumonia Severity Index
Study: 29368632
Drug: suPAR ≥10.22
Approvals — FDA: no, EMA: no, PMDA: no
Description: suPAR ≥10.22 ng/mL and syndecan-4 ≤6.68 ng/mL
Study: 29369091
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine 2.5 µg·kg
Study: 29369091
Drug: Oral pentobarbital
Normalized name: Pentobarbital
DrugBank: Pentobarbital (DB00312)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral pentobarbital 5 mg·kg
Study: 29369091
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine 1 µg·kg (rescue sedation)
Study: 29369664
Drug: Escitalopram, Duloxetine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram, Duloxetine, or Cognitive Behavior Therapy (CBT)
Study: 29370183
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant (OAC) resumption after ICH
Study: 29370229
Drug: Anticoagulants (ACs)
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulants (ACs) with or without antiplatelet (AP) therapy
Study: 29370795
Drug: Postpartum weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postpartum weight retention intervention including six weeks of interactive daily health texting, exercise assistance with baby carrier, home exercise program, pedometer provision, two live healthy eating and baby feeding workshops, and two 45-min home visits over one year
Study: 29370811
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg prednisolone daily added to standard of care
Study: 29371177
Drug: Automated mobile
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated mobile phone-based personalized daily step goals
Study: 29371475
Drug: Everolimus, 10
Normalized name: Everolimus, 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus, 10 mg daily
Study: 29371864
Drug: Loratadine tablets
Normalized name: Loratadine Tablets
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loratadine tablets
Study: 29372409
Drug: Solutions provided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solutions provided group
Study: 29372409
Drug: Solutions withheld
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solutions withheld group
Study: 29372461
Drug: Irinotecan (135
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan (135 mg/m²), oxaliplatin, and S-1 (OIS) regimen
Study: 29373071
Drug: Enzalutamide 160
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide 160 mg once per day until disease progression
Study: 29373602
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg BID apixaban
Study: 29373602
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg BID apixaban
Study: 29373711
Drug: Pioglitazone therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone therapy for 24 weeks
Study: 29373984
Drug: 12-week progressive,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-week progressive, strength and neuromuscular exercise group (SNG) with supervised training twice weekly
Study: 29373998
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy (laser group)
Study: 29373998
Drug: Light-emitting diode
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light-emitting diode (LED) therapy (LED group)
Study: 29375477
Drug: Liquid formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid formulation of r-hFSH/r-hLH (900/450 IU)
Study: 29375477
Drug: Freeze-dried formulation
Normalized name: BLACKBERRY MESOCARP FREEZE DRIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Freeze-dried formulation of r-hFSH/r-hLH (900/450 IU)
Study: 29377748
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (650 mg EPA and 350 mg DHA daily)
Study: 29377953
Drug: Ganciclovir gel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganciclovir gel, 0.15% 1cc 5 times a day for 6 weeks
Study: 29378056
Drug: Lysine intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine intake of 36.6 mg·kg-1·d-1 during early gestation
Study: 29378056
Drug: Lysine intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine intake of 50.3 mg·kg-1·d-1 during late gestation
Study: 29378547
Drug: Oral antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antipsychotic treatments (APT)
Study: 29378547
Drug: Other injectable
Normalized name: dihematoporphyrin ether Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other injectable antipsychotic treatments (APT)
Study: 29378547
Drug: Oral APT
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral APT
Study: 29380442
Drug: Locoregional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locoregional treatment (including Radiofrequency ablation and combination therapy)
Study: 29380442
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of RFA and transarterial chemoembolization
Study: 29380445
Drug: Self-reported non-adherence
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported non-adherence to immunosuppressive medication
Study: 29380445
Drug: Medication knowledge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication knowledge and trough levels
Study: 29381435
Drug: Selinexor 80
Normalized name: SELINEXOR 80MG WEEKLY PKT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selinexor 80 mg and dexamethasone 20 mg, both orally and twice weekly
Study: 29381834
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy consisting of thermal modalities, tissue mobilization, and upper extremity mobility exercises, with 8 weekly in-person sessions.
Study: 29382391
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of lopinavir/ritonavir and recombinant interferon-β1b with standard supportive care
Study: 29382510
Drug: Preoperative Renal
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative Renal Functional Reserve (RFR) measured by high oral protein load test
Study: 29382957
Drug: Citalopram treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram treatment (level 1 treatment)
Study: 29383572
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (30, 50 or 70 mg/day) for 104 weeks
Study: 29383782
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICS) completely withdrawn
Study: 29383782
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICS) stepped-down to a reduced dose
Study: 29384473
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MEG and fMRI data
Study: 29385166
Drug: Locomotor training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locomotor training (LT) on a treadmill using body-weight support for 80 daily one-hour sessions
Study: 29385376
Drug: 19-28z CAR
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 19-28z CAR T cells infusion
Study: 29385444
Drug: Oral doxycycline
Normalized name: doxycycline Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doxycycline (100 mg q12h)
Study: 29385444
Drug: Intravenous ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ceftriaxone (2 g q24h)
Study: 29385837
Drug: L-selectin
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-selectin
Study: 29385837
Drug: Insulin-like growth
Normalized name: Insulin-like growth factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-like growth factor-binding protein 3
Study: 29385837
Drug: Heparin cofactor
Normalized name: Heparin cofactor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin cofactor 2
Study: 29386196
Drug: Ibrutinib in
Normalized name: Product containing ibrutinib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib in combination with R-ICE (rituximab, ifosfamide, carboplatin, etoposide) at 840 mg daily
Study: 29386196
Drug: Ibrutinib in
Normalized name: Product containing ibrutinib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib in combination with R-ICE
Study: 29386195
Drug: Galinpepimut-S (multivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galinpepimut-S (multivalent WT1 peptide vaccine) administered as 6 vaccinations over 10 weeks, with potential for 6 additional monthly doses if in CR1.
Study: 29386249
Drug: DPP-4 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DPP-4 inhibitor therapy
Study: 29387020
Drug: Attachment-Based Compassion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attachment-Based Compassion Therapy (ABCT) combined with treatment as usual (TAU)
Study: 29387020
Drug: Relaxation (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation (active control group) combined with treatment as usual (TAU)
Study: 29387473
Drug: H5VLP vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: H5VLP vaccine co-administered with Alhydrogel
Study: 29387473
Drug: H5VLP vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: H5VLP vaccine co-administered with GLA-SE
Study: 29388903
Drug: FGln tracer
Approvals — FDA: no, EMA: no, PMDA: no
Description: FGln tracer (mean, 244 MBq ± 118, <100 μg) administered intravenously
Study: 29389078
Drug: 2% Tapinarof
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% Tapinarof cream
Study: 29389078
Drug: 1% Tapinarof
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% Tapinarof cream
Study: 29389360
Drug: hESC-derived cardiovascular
Normalized name: hESC-derived RPE
DrugBank: ASP-7317 (DB18549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hESC-derived cardiovascular progenitors (median dose 8.2 million)
Study: 29389444
Drug: Pantoprazole, ~1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole, ~1.2 mg/kg lean body weight (LBW)
Study: 29389444
Drug: Pantoprazole, LBW
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole, LBW dosing
Study: 29391051
Drug: 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days of high-dose amoxicillin
Study: 29391051
Drug: 10 days
Normalized name: AlleRx 10-day Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 days of high-dose amoxicillin (reference standard)
Study: 29391374
Drug: wP (whole-cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: wP (whole-cell pertussis) vaccine as the first vaccine dose
Study: 29391374
Drug: aP (subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: aP (subunit acellular pertussis) vaccine as the first vaccine dose
Study: 29391819
Drug: High flow
Normalized name: Blood Set High Flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: High flow rate (HFR) at 10.4 mL/s
Study: 29391819
Drug: Low flow
Normalized name: high mallow flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low flow rate (LFR) at 1.7 mL/s
Study: 29392234
Drug: Bupivacaine lozenges
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine lozenges (25 mg) taken up to every 2 hours for 7 days plus standard pain treatment minus topical lidocaine
Study: 29392234
Drug: Standard pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pain treatment including topical lidocaine
Study: 29392418
Drug: N-acetyl-L-cysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetyl-L-cysteine (NAC) supplementation (1 g/day)
Study: 29392418
Drug: Acute methionine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute methionine loading (MetLo) (0.1 g Met/kg mass weight)
Study: 29392450
Drug: Intravenous artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous artesunate (IV AS) at a maximum tolerated dose (MTD) of 18 mg/kg
Study: 29392450
Drug: Intravenous artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous artesunate (IV AS) at dosages of 12 mg/kg, 18 mg/kg, and 25 mg/kg
Study: 29393183
Drug: Chemotherapy (PCV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (PCV or temozolomide)
Study: 29394124
Drug: Pomalidomide plus
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide plus low-dose dexamethasone (LoDEX)
Study: 29394884
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG, n = 80), no treatment, usual recreational activities
Study: 29394907
Drug: Protective ventilation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protective ventilation strategy (VT set at 6-8 ml/kg, PEEP at 6-8 cmH2O)
Study: 29394907
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (VT set at 10-12 ml/kg, no PEEP or recruitment maneuvers)
Study: 29394908
Drug: daily calorie
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily calorie restriction (reduce habitual daily energy intake by 25%)
Study: 29394908
Drug: intermittent fasting
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intermittent fasting with calorie restriction (alternate between 24-hour periods of fasting and feeding to 150% of habitual daily energy intake)
Study: 29394908
Drug: intermittent fasting
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intermittent fasting without calorie restriction (alternate between 24-hour periods of fasting and feeding to 200% of habitual daily energy intake)
Study: 29394918
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily co-formulated tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) for up to 24 months; follow-up includes testing for HIV at 1 month, HIV and other sexually transmissible infections three-monthly, HCV annually, and renal function monitoring six-monthly.
Study: 29395867
Drug: Chemotherapy (platinum-based)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (platinum-based)
Study: 29395867
Drug: Chemotherapy (taxane)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (taxane)
Study: 29395867
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment during pregnancy
Study: 29396094
Drug: R-CHOP (rituximab
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP (rituximab plus cyclophosphamide [750 mg/m2], doxorubicin, vincristine, and prednisone) followed by radioimmunotherapy and maintenance rituximab for 4 years
Study: 29396857
Drug: FLAI-GO induction
Normalized name: Go-dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLAI-GO induction regimen (fludarabine 30 mg/sqm, cytarabine 2 g/sqm, idarubicin 10 mg/sqm, Gemtuzumab-Ozogamicin 3 mg/sqm)
Study: 29397139
Drug: Presurgical antiplatelet
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presurgical antiplatelet therapy (APT) prescribed in 95% of procedures; preoperatively discontinued in 15%.
Study: 29397225
Drug: Booster vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster vaccination with polygeline-free inactivated TBE vaccine (TBEvac)
Study: 29399054
Drug: Cladribine tablets
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cladribine tablets (CT) 3.5 mg/kg
Study: 29399258
Drug: Ingenol Disoxate
Normalized name: Ingenol disoxate
DrugBank: Ingenol disoxate (DB15109)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingenol Disoxate (LEO 43204), treatment duration not specified
Study: 29401002
Drug: Alpelisib 400
Normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alpelisib 400 mg once daily
Study: 29401002
Drug: Alpelisib 150
Normalized name: alpelisib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpelisib 150 mg twice daily
Study: 29401002
Drug: Alpelisib (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpelisib (various doses)
Study: 29401080
Drug: Intermittent oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent oxytocin pretreatment (alternating 10(-5) M and physiological salt solution every 15 minutes for 2 hours)
Study: 29402064
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of intravenous alteplase
Study: 29402243
Drug: Tyrosine kinase
Normalized name: Protein-tyrosine kinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine kinase inhibitors (TKIs), specifically gefitinib
Study: 29402319
Drug: Education and
Normalized name: zinc pyrithione Medicated Shampoo [Free and Clear]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education and treatment programme combined with flash glucose monitoring device
Study: 29402761
Drug: Fitbit One
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fitbit One worn daily throughout the 12-week intervention
Study: 29404331
Drug: 17.5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17.5 g/day cooked navy bean powder
Study: 29404331
Drug: 15 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g/day heat-stabilized rice bran
Study: 29404331
Drug: 9 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 g/day navy beans and 8 g/day rice bran
Study: 29404713
Drug: OnabotulinumtoxinA 155
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: OnabotulinumtoxinA 155 U every 12 weeks for 9 treatment cycles (108 weeks)